<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724252</url>
  </required_header>
  <id_info>
    <org_study_id>1571754</org_study_id>
    <nct_id>NCT04724252</nct_id>
  </id_info>
  <brief_title>Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in Children</brief_title>
  <official_title>Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine if the peri and post operative use of&#xD;
      gabapentin in children reduces the need for narcotics after thoracic surgery.&#xD;
&#xD;
      We hypothesize that patients who are given gabapentin will need fewer morphine equivalents&#xD;
      postoperatively than those who were not given gabapentin&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blind, placebo controlled, randomized study to explore the effects of&#xD;
      gabapentin peri and post operatively. Physician and families will be blinded to the&#xD;
      treatment.&#xD;
&#xD;
      60 subjects will be randomized in a 1:1 ratio to either:&#xD;
&#xD;
        -  Gabapentin treatment group&#xD;
&#xD;
        -  Placebo - control group&#xD;
&#xD;
      We aim to understand the impact that gabapentin use peri and post operatively has on:&#xD;
&#xD;
        1. opioid use based of IV morphine&#xD;
&#xD;
        2. pain scores&#xD;
&#xD;
        3. opioid related complications such as withdrawal&#xD;
&#xD;
        4. effects on the level of sedation&#xD;
&#xD;
        5. Possible adverse effects associated with use of gabapentin&#xD;
&#xD;
        6. Time to extubating&#xD;
&#xD;
      The duration of an individual subject's participation in the study will be 7 days or until&#xD;
      the patient is discharged from UC Davis Hospital, whichever occurs first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Children meeting criteria will be randomized in a 1:1 ratio using 4 blocked randomization to either gabapentin or placebo (in addition to standard of care pain control treatment):</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This study is a double-blind, placebo controlled, randomized study. Physician and families will be blinded to the randomization.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of pain medication needed.</measure>
    <time_frame>7 days post-operative or until discharge, whichever came first</time_frame>
    <description>Amount of pain medication needed after surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Gabapentin Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Given at a dose of 10mg/kg (max 600mg) perioperatively (immediately prior to surgery) followed by 3mg/kg/dose TID with first dose to be given starting at 8 hours post perioperative dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Given placebo which coincides with the active treatment group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Determine if the peri and post operative use of gabapentin in children reduces the need for narcotics after surgery.</description>
    <arm_group_label>Gabapentin Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control Arm</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age newborn to &lt; 18 years.&#xD;
&#xD;
          2. Gestational age to be minimum 38 weeks.&#xD;
&#xD;
          3. Undergo cardiac surgery via a sternotomy or thoracotomy.&#xD;
&#xD;
          4. Any Thoracic Surgery&#xD;
&#xD;
          5. Planned noncardiac surgery via a thoracotomy or Video Assisted Thoracotomy (VATS).&#xD;
&#xD;
          6. Surgery will result in an inpatient stay of at least 48 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of opioids within 30 days prior to study entry.&#xD;
&#xD;
          2. Renal Failure as defined by RIFLE Criteria.&#xD;
&#xD;
          3. History of seizures requiring active treatment.&#xD;
&#xD;
          4. History of chronic pain treated medically.&#xD;
&#xD;
          5. Diagnosis of Autism.&#xD;
&#xD;
          6. Unable to tolerate enteral medications.&#xD;
&#xD;
          7. Hematology/Oncology patients.&#xD;
&#xD;
          8. Parents/legal guardians unable to consent.&#xD;
&#xD;
          9. Participation in another clinical study presently or within the last 30 days&#xD;
&#xD;
         10. Pregnancy&#xD;
&#xD;
         11. Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carly Davis, BS</last_name>
      <phone>916-453-2132</phone>
      <email>cjddavis@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Beth Lawless, MS, RN</last_name>
      <phone>916-453-2133</phone>
      <email>mblawless@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gary Raff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thoracic surgery</keyword>
  <keyword>cardiac surgery via a sternotomy or thoracotomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

